Asymmetric Investing by Travis Hoium on HIMS

The host argues that Hims & Hers combines leadership in a large addressable market with opportunities to expand products and geography. He views peptides as an additional growth engine that could make the current valuation particularly attractive, while acknowledging competition, regulatory uncertainty and international execution risk.

The host believes Hims & Hers can sustain long-term revenue compounding through product expansion, international acquisitions, and a large healthcare opportunity. He expects growth to recover after disruption to compounded GLP-1 offerings.

Travis argues Hims & Hers is executing a long-term strategy to become a single, unified global healthcare brand (akin to Netflix or Uber), unifying its Hims/Hers branding, tech stack, and pharma deals across countries following acquisitions like Eucalyptus. He sees the recent Australia rebrand as symbolic of a much larger opportunity to become the dominant global aggregator of healthcare demand, driving subscriber growth, rising revenue per subscriber, and eventually a much higher valuation.

Travis views Hims & Hers as his biggest portfolio position, citing reaccelerating revenue growth after the GLP-1 compounding loophole closed, a new Novo Nordisk partnership, and an expanding 'healthcare aggregator' business model. He believes the company has significant room for margin expansion and multiple re-rating given its low EV/sales.

Travis views Hims & Hers as the biggest holding in his portfolio, believing the company is deliberately sacrificing short-term margins to acquire subscribers and build a long-term healthcare aggregator platform. He argues the recent stock drop is a short-term overreaction to margin compression, while the underlying growth trajectory (accelerating revenue, subscriber adds, expanding treatment categories) is strengthening.

Travis Hoium argues that Hims & Hers is building a genuine AI-native healthcare platform, combining a new doctor-plus-AI hybrid chat experience with smart scale data integration to create a data flywheel that differentiates it from generic chatbots and traditional healthcare providers. He believes this strengthens the company's long-term growth trajectory and justifies its position as his largest portfolio holding.

Travis argues the FTC lawsuit against Hims & Hers is a short-term headline, not a structural threat, and actually signals that the company is winning against incumbent pharma by disrupting the industry. He views the stock's 13% drop as a potential buying opportunity similar to the earlier Novo Nordisk lawsuit dip, citing the company's strong subscriber growth, transparent pricing, and small fines relative to its $2.4 billion revenue base.

The host views Hims & Hers as a healthcare demand aggregator with growing subscriber numbers, spending and supplier bargaining power. He sees potential for a valuation above $100 billion in a decade and is currently building a position to hold long term.

He sees Hims as a potentially large global healthcare platform built around direct consumer relationships, subscriptions, and personalized treatment. He expects a higher valuation if second-half growth accelerates, while describing the long-term investment as a high-upside, potentially binary outcome.

Hoium remains constructive on his largest holding as Hims & Hers expands its specialties, international footprint and data-driven treatment platform. He considers the valuation compelling if growth returns and presents a conditional scenario for a much higher enterprise-value-to-sales multiple.

The host sees Hims & Hers as a healthcare demand aggregator whose customer relationships, data and expanding specialties can reinforce one another and attract pharmaceutical supply. He regards the current sales multiple as a bargain, endorses maintaining his largest portfolio holding and sees potential for 100-fold returns if the company wins globally.

The host views Hims & Hers, his largest holding, as an emerging consumer healthcare platform with substantial investor upside if it compounds growth over a decade. Subscriber expansion, additional treatments and international acquisitions underpin the opportunity.